President Trump, joined by Nationwide Institutes of Well being Director Jay Bhattacharya and Well being and Human Providers Secretary Robert F. Kennedy Jr., talks about an govt order aimed toward lowering the price of pharmaceuticals.
Andrew Harnik/Getty Pictures
cover caption
toggle caption
Andrew Harnik/Getty Pictures
President Trump is taking purpose at U.S. drug costs with an govt order geared towards forcing drug corporations to match the decrease costs paid in different developed international locations.
If drugmakers do not do it voluntarily, the administration is threatening to immediately tie drug costs paid by authorities applications like Medicare to these paid in different international locations.
“Whoever is paying the bottom value, that is the value that we’ll get,” Trump mentioned in an announcement on the White Home, explaining what he known as “most favored nation” pricing.
He mentioned drugmakers must reduce their U.S. costs to the extent paid by different developed international locations—or face penalties. “If crucial, we’ll examine the drug corporations, and we’ll, specifically, examine the international locations which are doing this,” he mentioned. He additionally mentioned that the U.S. market could be opened to imports from different international locations.
Sufferers within the U.S. typically pay extra for medicine than sufferers in different international locations, largely as a result of different international locations have authorities well being care methods that set costs they’re keen to pay. The U.S., by and enormous, would not set costs, so drug corporations have extra freedom to see what costs the market right here will bear.
“We have been subsidizing different international locations all through the world” by paying larger costs, Trump mentioned on the White Home Monday, joined by leaders of federal well being companies.
The chief order lays out a number of approaches to decrease costs
The brand new govt order has a number of elements. It directs the U.S. Commerce Consultant and Division of Commerce to take motion in opposition to “unreasonable and discriminatory insurance policies” that decrease drug costs overseas, although it is not clear what authority the White Home has on this regard. It additionally directs Well being and Human Providers Secretary Robert F. Kennedy Jr. to facilitate direct–to-consumer gross sales that bypass medical health insurance at decrease costs.
The order says that inside 30 days the administration will give value targets to drugmakers “to carry costs for American sufferers according to comparably developed nations.” The order lays out actions the administration would take if drugmakers do not comply voluntarily, resembling rulemaking to impose the costs. It is unclear within the quick time period what authorized authority the administration must implement the order.
Trump mentioned he would not suppose the transfer would damage drug corporations’ potential to become profitable as a result of they’ll put strain on different international locations to make up the distinction by elevating their costs. “Europe’s going to should pay a bit bit extra,” Trump mentioned. “The remainder of the world goes to should pay a bit bit extra, and America goes to pay quite a bit much less.”
Trump teased the newest “most favored nation” value coverage on Fact Social Sunday night time, prompting the commerce group Pharmaceutical Analysis and Producers of America, or PhRMA, to return out in opposition to the chief order, calling it a “unhealthy deal for American sufferers.”
After the chief order was introduced, PhRMA president and CEO Steve Ubl mentioned in an announcement: “To decrease prices for Individuals, we have to tackle the actual causes U.S. costs are larger: overseas international locations not paying their justifiable share and middlemen driving up costs for U.S. sufferers.” He added, “The Administration is correct to make use of commerce negotiations to drive overseas governments to pay their justifiable share for medicines. U.S. sufferers shouldn’t foot the invoice for international innovation.”
Most favored nation pricing was proposed earlier than
Trump initially signed an govt order on most favored nation pricing in late 2020 throughout his first time period that will have tied Medicare Half B drug costs to these in different international locations. However the govt order confronted court docket challenges and was in the end dropped by the Biden administration. On the marketing campaign path final yr, Trump mentioned he would reinstate probably the most favored nation govt order from 2020, however a video about it disappeared from Trump’s 2024 marketing campaign web site.
Medicare started negotiating drug costs for the primary time in the course of the Biden administration in 2024, below new authority granted by the Inflation Discount Act. The brand new decrease Medicare costs for the primary 10 medicine will not go into impact till January 2026, however the reductions vary from 79% for diabetes drug Januvia to 38% for blood most cancers drug Imbruvica. Now, the Trump administration is negotiating the second batch of drug costs for 15 medicines in accordance with the regulation.
In the course of the White Home announcement, Dr. Mehmet Oz, who leads the Facilities for Medicare and Medicaid Providers below Trump, identified that even the decrease negotiated Medicare costs are larger than what folks pay in Europe for a similar merchandise. “Half the time we’re paying thrice greater than is paid in different international locations. It would not make any sense for the system.”
Oz says the brand new govt order will carry these costs down even additional.
